Obecabtagene autoleucel

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Autolus Limited, Memorial Sloan Kettering Cancer Center

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic Leukemia (ALL)Lupus Nephritis

Phase 2

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

RecruitingNCT07053059

M.D. Anderson Cancer CenterAcute Lymphocytic Leukemia (ALL)

Start: 2025-08-26End: 2030-05-31Target: 30Updated: 2026-08-12

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

RecruitingNCT07053800

Autolus LimitedLupus Nephritis

Start: 2026-01-16End: 2029-10-01Target: 35Updated: 2026-08-24

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

RecruitingNCT07400029

Memorial Sloan Kettering Cancer CenterAcute Lymphoblastic Leukemia

Start: 2026-02-03End: 2029-02-01Target: 40Updated: 2026-08-20